
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Sunscreen creams cannot fully protect people against an increasingly common form of skin cancer, according to research published in late September.






